Newer obesity drugs linked to fewer alcohol-related hospitalizations for people with alcohol dependence. Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes among people with alcohol use disorder was associated with a reduction in alcohol-related hospital admissions, according to a study published online in the open-access journal BMJ Open.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes among people with alcohol use disorder was associated with a reduction in alcohol-related hospital admissions, according to a study published online in the open-access journal BMJ Open.
- Ponto de atenção: newer.
- Ponto de atenção: obesity.
- Ponto de atenção: drugs.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
